$Pharmaron Beijing Co., Ltd.* (03759.HK)$It rose nearly 6% in intraday trading. As of press time, it rose 5.52% to HK $46.85, with a turnover of nearly HK $100 million.

On the news side, Pharmaron Beijing Co., Ltd.* announced that Pharmaron Beijing Co., Ltd.* (Ningbo) Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, (referred to as "Ningbo macromolecule Company") is currently planning to increase capital and shares in the form of equity financing, the expected amount of financing is not more than 300 million US dollars, the specific counterparty of the transaction has not yet been determined, including the company's related parties / related persons.

It is reported that the purpose of this matter is to further speed up the construction of R & D service capacity of macromolecular drugs and cell and gene therapy, and to improve the operation capacity of macromolecule and cell and gene therapy service plate.